These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17973783)

  • 21. The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.
    Guillot B; Portalès P; Thanh AD; Merlet S; Dereure O; Clot J; Corbeau P
    Br J Dermatol; 2005 Apr; 152(4):690-6. PubMed ID: 15840100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-alpha.
    Duensing S; Hadam M; Körfer A; Schomburg A; Menzel T; Grosse J; Kirchner H; Poliwoda H; Atzpodien J
    Mol Biother; 1992 Dec; 4(4):170-3. PubMed ID: 1282326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma.
    Recchia F; Candeloro G; Necozione S; Fumagalli L; Bratta M; Rea S
    Anticancer Drugs; 2008 Feb; 19(2):201-7. PubMed ID: 18176117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In-vitro activation of natural killer cells from regional lymph nodes of melanoma patients with interleukin-2 and interleukin-15.
    Vuletić AM; Jovanić IP; Jurišić VB; Milovanović ZM; Nikolić SS; Tanić NT; Konjević GM
    Melanoma Res; 2015 Feb; 25(1):22-34. PubMed ID: 25380182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased expression of pSTAT, IRF-1 and DAP10 signalling molecules in peripheral blood lymphocytes of patients with metastatic melanoma.
    Mirjačić Martinović K; Srdić-Rajić T; Babović N; Džodić R; Jurišić V; Konjević G
    J Clin Pathol; 2016 Apr; 69(4):300-6. PubMed ID: 26442832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distribution of several activating and inhibitory receptors on CD3(-)CD56(+) NK cells in regional lymph nodes of melanoma patients.
    Vuletić A; Jurišić V; Jovanić I; Milovanović Z; Nikolić S; Konjević G
    J Surg Res; 2013 Aug; 183(2):860-8. PubMed ID: 23522458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.
    Maxwell W; McDevitt J; Reid I; Sharpe I; Feighery C; Tanner WA; Emmons R; Monson JR
    Eur J Surg Oncol; 1993 Jun; 19(3):265-72. PubMed ID: 8314385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients.
    Konjević G; Mirjacić Martinović K; Vuletić A; Jović V; Jurisić V; Babović N; Spuzić I
    Clin Exp Metastasis; 2007; 24(1):1-11. PubMed ID: 17295095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An increase in the absolute count of CD56dimCD16+CD69+ NK cells in the peripheral blood is associated with a poorer IVF treatment and pregnancy outcome.
    Thum MY; Bhaskaran S; Abdalla HI; Ford B; Sumar N; Shehata H; Bansal AS
    Hum Reprod; 2004 Oct; 19(10):2395-400. PubMed ID: 15319390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study of IL-2 receptor expression after chemoimmunotherapy in patients treated for metastatic malignant melanoma.
    Mouawad R; Ichen M; Rixe O; Benhammouda A; Vuillemin E; Weil M; Khayat D; Soubrane C
    Clin Exp Immunol; 1994 Sep; 97(3):342-6. PubMed ID: 8082289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increase of CD69, CD161 and CD94 on NK cells in women with recurrent spontaneous abortion and in vitro fertilization failure.
    Ghafourian M; Karami N; Khodadadi A; Nikbakht R
    Iran J Immunol; 2014 Jun; 11(2):84-96. PubMed ID: 24975965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy.
    Lesinski GB; Kondadasula SV; Crespin T; Shen L; Kendra K; Walker M; Carson WE
    J Natl Cancer Inst; 2004 Sep; 96(17):1331-42. PubMed ID: 15339971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detailed analysis of peripheral blood natural killer cells in women with repeated IVF failure.
    Sacks G; Yang Y; Gowen E; Smith S; Fay L; Chapman M
    Am J Reprod Immunol; 2012 May; 67(5):434-42. PubMed ID: 22296517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanoma.
    Hernberg M; Mattila PS; Rissanen M; Hansson J; Aamdal S; Bastholt L; von der Maase H; Schmidt H; Stierner U; Tarkkanen J
    J Immunother; 2007 Oct; 30(7):773-9. PubMed ID: 17893569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
    Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in immunological parameters after combination adjuvant therapy with intravenous DTIC, ACNU, and VCR, and local injection of IFN-beta (DAV + IFN-beta therapy) into malignant melanoma.
    Umeda T; Aoki K; Yokoyama A; Ohara H; Hayashi O; Tanaka K; Nishioka K
    J Dermatol; 1998 Sep; 25(9):569-72. PubMed ID: 9798342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of natural killer (NK) receptors on NK (CD3-/CD56+), T (CD3+/CD56-) and NKT-like (CD3+/CD56+) cells after heart transplantation.
    Aguilar P; Mathieu CP; Clerc G; Ethevenot G; Fajraoui M; Mattei S; Faure GC; Bene MC
    J Heart Lung Transplant; 2006 Feb; 25(2):200-5. PubMed ID: 16446221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NK cell activity in tuberculosis is associated with impaired CD11a and ICAM-1 expression: a regulatory role of monocytes in NK activation.
    Schierloh P; Alemán M; Yokobori N; Alves L; Roldán N; Abbate E; del C Sasiain M; de la Barrera S
    Immunology; 2005 Dec; 116(4):541-52. PubMed ID: 16313368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of activation of human peripheral blood NK cells at the single cell level by Echinacea water soluble extracts: recruitment of lymphocyte-target conjugates and killer cells and activation of programming for lysis.
    Gan XH; Zhang L; Heber D; Bonavida B
    Int Immunopharmacol; 2003 Jun; 3(6):811-24. PubMed ID: 12781698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.